Oral butyrate for mildly to moderately active Crohn's disease

A. Di Sabatino, R. Morera, R. Ciccocioppo, P. Cazzola, S. Gotti, F. P. Tinozzi, S. Tinozzi, G. R. Corazza

Research output: Contribution to journalArticle

Abstract

Background: Butyrate exerts anti-inflammatory effects in experimental colitis and on Crohn's disease lamina propria mononuclear cells in vitro. Aim: To explore the efficacy and safety of oral butyrate in Crohn's disease. Methods: Thirteen patients with mild-moderate ileocolonic Crohn's disease received 4 g/day butyrate as enteric-coated tablets for 8 weeks. Full colonoscopy and ileoscopy were performed before and after treatment. Endoscopical and histological score, laboratory data, Crohn's disease activity index and mucosal interleukin (IL)-1β, IL-6, IL-12, interferon-γ, tumour necrosis factor-α and nuclear factor-kappa B (NF-κB) were assessed before and after treatment. Results: One patient withdrew from the study, and three patients did not experience clinical improvement. Among the nine patients (69%) who responded to treatment, seven (53%) achieved remission and two had a partial response. Endoscopical and histological score significantly improved after treatment at ileocaecal level (P <0.05). Leucocyte blood count, erythrocyte sedimentation rate and mucosal levels of NF-κB and IL-1β significantly decreased after treatment (P <0.05). Conclusions: Oral butyrate is safe and well tolerated, and may be effective in inducing clinical improvement/remission in Crohn's disease. These data indicate the need for a large investigation to extend the present findings, and suggest that butyrate may exert its action through downregulation of NF-κB and IL-1β.

Original languageEnglish
Pages (from-to)789-794
Number of pages6
JournalAlimentary Pharmacology and Therapeutics
Volume22
Issue number9
DOIs
Publication statusPublished - Nov 1 2005

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Oral butyrate for mildly to moderately active Crohn's disease'. Together they form a unique fingerprint.

  • Cite this